Related Party Transactions

9 Months Ended

Sep. 30, 2021

13. Related party transactions

The table below sets forth the major related party and the relationship with the Group as of September 30, 2021:


Company Name		Relationship with the Group
MEDx (Suzhou) Translational Medicine Co., Ltd.		Significant influence held by Samantha Du’s (Director, Chairwoman and Chief Executive Officer of the Company) immediate family

For the three and nine months ended September 30, 2021, the Group incurred $96 and $303

research and development expense with MEDx (Suzhou) Translational Medicine Co., Ltd. for product research and development services, respectively. The Group incurred $233 and $417

in research and development expense for the three and nine months ended September 30, 2020, respectively. All of the transactions are carried out with normal business terms and are on arms’ length basis.